Solventum (NYSE:SOLV) Stock Rating Upgraded by Wall Street Zen

by · The Markets Daily

Solventum (NYSE:SOLV – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Monday.

A number of other research firms have also commented on SOLV. Wells Fargo & Company raised their price objective on shares of Solventum from $75.00 to $79.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Piper Sandler reissued an “overweight” rating and set a $94.00 target price (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a research note on Tuesday, July 1st. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Finally, KeyCorp started coverage on shares of Solventum in a report on Friday, June 6th. They issued a “sector weight” rating on the stock. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Solventum presently has an average rating of “Hold” and a consensus price target of $85.75.

Get Our Latest Report on SOLV

Solventum Price Performance

NYSE SOLV opened at $71.79 on Monday. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The firm has a market capitalization of $12.45 billion, a PE ratio of 33.24, a P/E/G ratio of 1.77 and a beta of 0.53. Solventum has a 12 month low of $60.70 and a 12 month high of $85.92. The company’s 50 day simple moving average is $73.70 and its 200 day simple moving average is $72.80.

Solventum (NYSE:SOLV – Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities research analysts forecast that Solventum will post 6.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC bought a new position in shares of Solventum during the 1st quarter worth about $216,000. Bessemer Group Inc. boosted its position in shares of Solventum by 17.1% during the 1st quarter. Bessemer Group Inc. now owns 1,963 shares of the company’s stock valued at $150,000 after acquiring an additional 287 shares in the last quarter. Comerica Bank boosted its position in shares of Solventum by 39.7% during the 1st quarter. Comerica Bank now owns 77,725 shares of the company’s stock valued at $5,910,000 after acquiring an additional 22,079 shares in the last quarter. CW Advisors LLC acquired a new stake in shares of Solventum during the 1st quarter valued at about $312,000. Finally, Raymond James Financial Inc. boosted its position in shares of Solventum by 12.0% during the 1st quarter. Raymond James Financial Inc. now owns 315,099 shares of the company’s stock valued at $23,960,000 after acquiring an additional 33,790 shares in the last quarter.

About Solventum

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Articles